Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Reduced Intensity (Fanconi)-New York Medical College-Leukemia-Lymphoma-Bone Marrow Failure-Immunodeficiencies-Histiocytosis-Sickle Cell Disease-Beta Thalassemia-Inborn Errors of Metabolism
- Development stage
- Unknown
- Lead developer
- New York Medical College
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Recombinant Proteins and Enzymes, Cell Therapies
- Administration
- Intravenous
01
Overview
This regimen is a specific reduced-intensity conditioning (RIC) protocol developed by New York Medical College for pediatric and young adult patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). It is primarily designed for patients with Fanconi anemia or other high-risk conditions including leukemia, lymphoma, bone marrow failure, and various non-malignant disorders. The protocol combines immunoablative and myelosuppressive agents—specifically fludarabine, cyclophosphamide, and horse antithymocyte globulin (ATG)—with a single fraction of total body irradiation (TBI). This conditioning is followed by the infusion of CD34+ selected stem cells, a technique intended to provide a pure population of hematopoietic progenitors while depleting T-cells to reduce the incidence and severity of graft-versus-host disease (GVHD) in recipients of partially matched or unrelated donor grafts.
- Brand names
- CliniMACS
- Other names
- Reduced Intensity (Fanconi)NYMC RIC Protocol for Fanconi AnemiaCD34+ Selection in Allogeneic Stem Cell Transplantation
Beyond the preview
Go deeper on Reduced Intensity (Fanconi)-New York Medical College-Leukemia-Lymphoma-Bone Marrow Failure-Immunodeficiencies-Histiocytosis-Sickle Cell Disease-Beta Thalassemia-Inborn Errors of Metabolism.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Reduced Intensity (Fanconi)-New York Medical College-Leukemia-Lymphoma-Bone Marrow Failure-Immunodeficiencies-Histiocytosis-Sickle Cell Disease-Beta Thalassemia-Inborn Errors of Metabolism.